|
|
 |
|
Viewing report
|
|
|
|
Premium Company Profile Cytogen
Datamonitor, Oct 2007, Pages: 46
Introduction
Cytogens clinical development initiatives currently focus on new indications for existing product candidates namely Quadramet and ProstaScint, as well as its product candidate, CYT-500 which is in the Phase I stage of drug development process for the treatment of prostate cancer.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Cytogen is focused on the development and commercialization of biopharmaceuticals for various oncology indications. Cytogen derives its revenues from marketing of pharmaceutical products and from license and contract under collaborative agreements received for the research services that the company provides to third parties. Cytogens biggest contributor to revenue growth during 2002-2006 was product sales of ProstaScint and Quadramet. Cytogens Launch-Core-Expiry (LCE) profile indicates that the greatest growth between 2006 and 2010 is exhibited by the expiry portfolio, demonstrated by an absolute annual increase in sales of $37 million.
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Cytogen Corporation - SWOT Analysis
Analysis of Cytogen Corporation
Cytogen Corporation - SWOT Framework Analysis
CYTOGEN - World'Vest Base Dossier
Cytogen Corporation-Therapeutic Competitors
Cytogen Corporation Company Profile
Hospira, Inc. Medical Equipment Company Report: Medical Device Company Analysis Covering key Information Relating to Company Market Share by Sector and Country, Financial, SWOT and Value Chain Analysis
Viropharma Incorporated: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Executive Appointment Call - Cytogen Corp. - Earnings Transcript
Cytogen Corporation-Financial Company Report
Cytogen Corporation-Detailed Product Pipeline
|
|
|
|
